Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA grants final approval for Acarbose tablets ANDA: Mylan Pharma
Mylan Pharmaceuticals, a subsidiary of Mylan Inc, has claimed that its Acarbose tablets is the generic version of Bayer’s Precose tablets, a treatment to be used with diet
Mylan Pharmaceuticals, a subsidiary of Mylan Inc, has claimed that its Acarbose tablets is the generic version of Bayer’s Precose tablets, a treatment to be used with diet
Under the plan, R5 Pharma, a subsidiary of Aesica Pharmaceuticals, plans to build a new analytical chemistry laboratory this spring with the second stage of construction completing in
The EverFlex+ Self-Expanding Peripheral Stent System is the advanced version of EverFlex stent technology for the treatment of peripheral arterial disease. The new EverFlex+ system is designed to
The joint venture is expected to be renamed as Vertellus Specialty Materials (India) for the marketing and distribution of specialty chemicals globally Vertellus Specialties is the majority partner
The new system, which will help in the production of self-adhesive labels, consists of machine mounted cameras that compare every label produced to the customer’s approved artwork. The
TransPharma’s ViaDor drug delivery system incorporates a handheld electronic device, which creates microscopic passageways through the outer layer of the skin allowing for transdermal delivery of a wide
PecFent is indicated for the treatment of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. According to Archimedes Pharma, the SMC’s
The research centre was dedicated by the Chancellor of Manipal University, Ramdas Pai. Pai said the safe conduct of studies for Indian and global companies, leveraging the scientific
The data, compiled from 479 patients enrolled in a randomized controlled trial being conducted to obtain US Food and Drug Administration PMA clearance for the device, showed that
The Phase III trial will enroll approximately 250 patients across Japan, Singapore, China, Korea, and Taiwan, and is scheduled to run until June 2013. In the trial, three